Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
The Motley Fool June 28, 2005 Brian Gorman	Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
The Motley Fool January 26, 2007 Billy Fisher	A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note.
The Motley Fool May 2, 2005 Brian Gorman	Cardinal Health Perks Up The drug distribution company is working through its problems, which should make for a brighter fiscal 2006. Investors, take note.
BusinessWeek November 24, 2003 Roger O. Crockett	Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas.
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
The Motley Fool January 2, 2004 Alyce Lomax	A Bitter Pill for Amerisource Veterans ditch Amerisource for rival; investors punish the entire pharmaceutical distribution industry.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool July 28, 2004 Brian Gorman	Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool November 7, 2007 Billy Fisher	Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment.
The Motley Fool May 18, 2005 Brian Gorman	Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching.
The Motley Fool June 14, 2004 Brian Gorman	Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool July 1, 2004 W.D. Crotty	Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
ifeminists December 28, 2005 Tony Zizza	If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs.
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
BusinessWeek August 30, 2004 Gene G. Marcial	PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool August 20, 2010 Brian Orelli	Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool May 20, 2004 Tom Taulli	Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
BusinessWeek February 25, 2010 Weintraub & Tirrell	Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed.
The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
BusinessWeek March 20, 2006 Gene G. Marcial	Lilly Is Starting To Bloom Big pharma has been in the doldrums for years, ravaged by generic rivals, class actions, and trickling product pipelines. But some pockets are perking up.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool May 6, 2005 W.D. Crotty	McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model.
The Motley Fool June 27, 2011 Brandon Glenn	Cardinal Health Products Won't Be in Cleveland Medical Mart (or Any Other) Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health has had an apparent change of opinion.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool June 10, 2005 Stephen D. Simpson	The High Cost of Diabetes Settling claims related to Zyprexa was probably the best of a bad set of choices for Eli Lilly. Investors need to remember to incorporate this as a risk factor for all drug companies.
The Motley Fool April 15, 2005 Brian Gorman	Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.